Conjunctival sac fluid contains elevated levels of soluble Trail: Implications for the anti-tumoral surveillance of the anterior surface of the eye

Journal of Cellular Physiology

Volumn 218, Issue 1, 2009, Pages 199-204

  Secchiero, Paola ^a   Lamberti, Giuseppe ^a   Corallini, Federica ^a   Melloni, Elisabetta ^a   Guarnotta, Carla ^b   Sebastiani, Adolfo ^a   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RECOMBINANT PROTEIN; TNFRSF11B PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL; PHOTOREFRACTIVE KERATECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; BODY FLUID; CONJUNCTIVA; CORNEA; CYTOLOGY; DRUG EFFECT; EPITHELIUM CELL; EYE TUMOR; METABOLISM; PHYSIOLOGY; SOLUBILITY; TUMOR CELL LINE;

APOPTOSIS; BODY FLUIDS; CELL LINE, TUMOR; CONJUNCTIVA; CORNEA; EPITHELIAL CELLS; EYE NEOPLASMS; HUMANS; OSTEOPROTEGERIN; PHOTOREFRACTIVE KERATECTOMY; RECOMBINANT PROTEINS; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 58149171658     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21589     Document Type: Article

References (29)

1. Ashkenazi A. 2008. Targeting the extrinsic apoptosis pathway in cancer. Cyt Growth Fact Rev 19:325-331.
2. Babar TF, Khan MN, Hussain M, Shah SA, Khan MY, Khan MD. 2007. Spectrum of ocular surface squamous neoplasia. J Coll Phys Surg Pak 17:344-346.
3. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, Zauli G. 2005. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166:557-563.
4. Cassatella MA, HuberV, Calzetti F, Margotto D, Tamassia N, Peri G, Mantovani A, Rivoltini L, Tecchio C. 2006. Interferon-activated neutrophils store a TNF-related apoptosis inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators.J Leuk Biol 79:123-132.
5. Cather JC, Soparkar CN, Nelson BR. 1999. Ocular melanoma. Cutis 63:285-292.
6. Choi JW. 2005. Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults. Ann Hematol 84:728-733.
7. Corazza N, Brumatti G, Schaer C, Cima I, Wasem C, Brunner T. 2004. TRAIL and immunity: More than a license to kill tumor cells. Cell Death Differ II(Suppl 2): S122-125.
8. Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bermis K, Zamai L, Miscia S, Zauli G. 2004. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis- inducingligand (TRAIL)-mediated cytotoxicityby selective up-regulation of TRAIL-Rl. Blood 97:2596-2603.
9. Eidsmo L, FluurC, Rethi B, Eriksson Ygberg S, Ruffin N, De Milito A, Akuffo H,Chiodi F.2007. FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure of Leishmania major. Am J Pathol 170:227-239.
10. Ferguson TA, Griffith TS. 1997. A vision of cell death: Insights into immune privilege. Immunol Rev 156:167-184.
11. Greenlee RT, Hill-Harmon MB, MurrayT, Thun M. 200l. Cancer statistics. CACancer JClin 51:15-36.
12. Jo M,Kim TH, Seol DW,Esplen JE, DorkoK, BilliarTR, Strom SC.2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567.
13. Koschny R, Walczak H, Ganten TM. 2007. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 85:923-935.
14. Lamy V, Roussi S, Chaabi M, Gossè F, Schall N, Lobstein A, Raul F. 2007. Chemopreventive effects of lupulone, a hop (beta)-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Carcinogenesis 28:1575-1581.
15. Lee H, Herndon JM, Barreiro R, Griffith TS, Ferguson TA. 2002. TRAIL: A mechanism of tumor surveillance in an immune privileged site. J Immunol 69:4739-4744.
16. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J. 2005. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 45:1018-1024.
17. Ouhtit A, Gorny A, Muller HK, Hill LL, Owen-Schaub L, Ananthaswamy HN. 2000. Loss of Fas-ligand expression in mouse keratinocytes during UV carcinogenesis. Am J Pathol 157:1975-1981.
18. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. 2002. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 100:2421-2429.
19. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, Zauli G. 2004. TRAIL regulates normal erythroid maturation through an ERK-dependentpathway. Blood 103:517-522.
20. Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, Fanin R, Zauli G. 2005.Aberrantexpression ofTRAIL in B chroniclymphocyticleukemia(B-CLL)cells.J Cell Physiol 205:246-252.
21. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, Cavazzini F, Campioni D, Fanin R, Cuneo A, Zauli G. 2006a. Functional integrityof the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122-4129.
22. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. 2006b. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169:2236-2244.
23. Stander S, Schwarz T. 2005. Tumor necrosis factor-related apoptosis-inducingligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer. Am J Dermatopathol 27:116-121.
24. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB. 2007. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-l. J Clin Oncol 25:1390-1395.
25. Vigneswaran N, Baucum DC, Wu J, Loou Y, Bouquot J, Muller S, Zacharias W. 2007. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) butnotits receptors during oral cancer progression. BMC Cancer 7:108.
26. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W,JonesJ, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. l999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. NatMed 5:157-163.
27. Whitcup SM, de Smet MD, Rubin BI, Palestine AG, Martin DF, Burnier M Jr, Chan CC, Nussenblatt RB. 1993. Intraocular lymphoma: Clinical and histopathologic diagnosis. Ophthalmology 100:1399-1406.
28. Zauli G, Secchiero P. 2006. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cyt Growth Fact Rev 17:245-257.
29. Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, Smyth MJ. 2005. TRAIL deficiency accelerates hematological malignancies. J Immunol 175:5586-5590.